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table 1). Here, we present the 2012 update of these guidelines 
focusing on modifications performed for the 2012 version. 
The full version of the update is available online in PDF for-
mat (www.ago-online.de, ‘Leitlinien’) [2] in an English and a 
German version.
Early Detection and Diagnosis
Considering early detection and diagnosis of breast cancer, 
there were no changes or modifications of the current recom-
mendations compared to 2011. New data from 2 recent trials 
from The Netherlands [193] and Sweden [97], however, con-
firm the AGO recommendation for mammographic screening 
also in younger women 40–50 years of age (LoE 1bB, AGO +).
Breast Cancer Risk and Prevention
There were no clinically relevant changes in the AGO recom-
mendations concerning breast cancer risk and prevention 
compared to 2011. On the other hand, there were some 
 important publications stimulating further investigations. 
In 2010, RAD51C was identified as the 3rd high-risk gene 
for breast and ovarian cancer, which is, however, rarely 
 mutated [124]. RAD51C constitutes a proof of concept for the 
existence of more, yet very rarely affected high-risk genes. 
Recently, it was further shown by Loveday et al. [117] that 
germline mutations in RAD51D may confer susceptibility to 
ovarian cancer.
Poly(ADP-ribose) polymerase (PARP) inhibitors impair 
base excision repair during mitosis [26, 67]. In patients with 
metastatic triple-negative breast cancer (breast cancer antigen 
(BRCA) deficient), phase II studies with PARP inhibitors 
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suggested that this genetically defined subgroup might benefit 
from PARP inhibitor treatment [143]. However, in a phase III 
trial, efficacy has not been confirmed on a significant level 
[92].
In a large prospective trial (n = 4560) including postmeno-
pausal women with a moderately increased life-time risk to 
develop invasive breast cancer, the aromatase inhibitor (AI) 
exemestane significantly reduced invasive breast cancer oc-
currence. Whether the lowered incidence also transfers into 
reduced breast cancer-related mortality is still under investi-
gation [88] (AGO recommendation unchanged: LoE 1bA, 
AGO +).
Lesions of Uncertain Malignant Potential (B3) –  
ADH, LIN, FEA
In the 2012 update, the AGO recommendations concerning 
lobular intraepithelial neoplasia (LIN) were modified. LIN 
 includes atypical lobular hyperplasia (ALH) and lobular 
 carcinoma in situ (LCIS/CLIS). LIN is categorized as lesion 
of uncertain malignant potential (B3) if the criteria for pleo-
morphic LIN and LIN with necrosis or LIN with extensive 
 involvement of lobules are not fulfilled, which may qualify for 
B5a. These lesions are considered to carry an increased risk 
[74, 142, 180], but there is only little evidence to support this 
conclusion. A grading system (LIN 1 to LIN 3) has been 
 suggested as a tool for a more precise estimation of the indi-
vidual risk; however, validation of this system has yet to be 
performed [168, 180].
Since LIN is frequently associated with invasive cancer, 
which may not be represented in core needle or vacuum- 
assisted biopsies, open excisional biopsy is necessary if careful 
correlation with imaging is inconclusive (LoE 2bC, AGO ++) 
[31, 65, 134, 170, 155].
LIN at the margins of a resection specimen is considered 
as incidental finding; thus, no further surgery or re-excision 
has to be performed, provided that the imaging abnormality 
has been removed (LoE 3aC, AGO ++) [24, 65, 161]. Like-
wise, LIN accompanying intraductal or invasive carcinoma in 
patients with breast-conserving surgery (BCS) necessitates 
no further resection (LoE 2aC, AGO ++). Nevertheless, if 
pleomorphic LIN or LIN with necrosis is diagnosed, complete 
resection of the lesion is advised (LoE 5D, AGO ++) [39].
Ductal Carcinoma in situ
Only little clinically relevant modifications were made in 
2012. Focality is considered as a strong prognostic factor with 
regard to the risk of local-/locoregional recurrence in ductal 
carcinoma in situ (DCIS). However, biological factors as 
 estrogen receptor (ER), progesterone receptor (PR), human 
epidermal growth factor receptor 2 (HER2), cyclooxygenase 
(COX), p16, or Ki-67 do not add relevant prognostic informa-
tion. Also, the recently developed polymerase chain reaction 
(PCR)-based multi-gene DCIS score [214] requires further 
validation before being recommended for routine clinical use.
Pathology
Pathological diagnosis is crucial and the prerequisite of diag-
nosis, prognostic assessment, surgical, radiotherapeutical and 
medical therapy. It includes histopathological diagnosis of 
needle biopsy specimens, correlation with the imaging [73], 
differential diagnosis of the individual tumor, margin analysis, 
and also immunohistochemistry (IHC) for therapy-relevant 
markers such as ER, PR, and HER2.
With regard to core needle biopsy or vacuum-assisted 
 biopsy of mammographically suspicious lesions, excellent data 
are provided to use B-categorization for the description of 
needle biopsy specimens (LoE 1bB, AGO ++) [20, 173]. It is 
recommended to communicate the histopathological result 
within 24 h (at least dignity; LoE 5D, AGO +). We highly rec-
ommend immunohistological analysis of ER, PR and HER2 
also in the needle biopsy specimens (3bC, AGO ++) [112, 116, 
178]. Fine-needle aspiration cytology does not represent state 
of the art for diagnosis of lumps or Breast Imaging Report 
and Data System (BI-RADS) IV/V lesions (LoE 5D, AGO –) 
[107, 196]. However, although sensitivity is low, cytological 
examination of aspirated liquid from breast cysts or speci-
mens of nipple secretion may be helpful in many cases (LoE 
5D, AGO +). Concerning handling and reporting of core 
 needle biopsies, it is strongly recommended to participate in 
a quality assurance program (LoE 3D, AGO ++) [5, 37, 108, 
114].
Sentinel lymph node excision may be an indication for 
 immediate pathological analysis including frozen sections. 
However, it seems to be worthwhile only if it is followed by a 
Table 1. AGO grades of recommendation
++ This investigation or therapeutic intervention is highly beneficial for patients, can be recommended without restriction, and should  
be performed.
+ This investigation or therapeutic intervention is of limited benefit for patients and can be performed.
+/– This investigation or therapeutic intervention has not shown benefit for patients and may be performed only in individual cases.  
According to current knowledge a general recommendation cannot be given.
– This investigation or therapeutic intervention can be of disadvantage for patients and might not be performed.
–/– This investigation or therapeutic intervention is of clear disadvantage for patients and should be avoided or omitted in any case.
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are highly suggestive for therapeutic decisions, it must not be 
disregarded that there is no generally accepted and proven 
translation into immunohistochemical counterparts, neither 
with regard to markers nor to thresholds [35, 36, 139, 152, 
171].
In terms of practical consequences, re-labeling of clinically 
established and immunohistochemically defined subgroups 
may be useful (ER/PR+ for luminal type, HER2+ for HER2-
enriched type, triple-negative for basal type). The basal type 
shows an 80% overlap with the triple-negative subgroup of 
ductal invasive breast cancer (ER < 1% and PR < 1% and 
HER2 0/1+2+ non-amplified, ratio < 2.0). None of the avail-
able markers (Ki-67, grading, recurrence score, etc.) can reli-
ably discriminate between luminal A and luminal B type [35].
Although derived from RNA expression studies, RNA 
measurements are not suited for the definition of intrinsic 
types for purposes of therapy [49].
With regard to the Genomic Health Recurrence Score 
(Oncotype DX®), recently published data suggest that it may 
be substituted by a sophisticated algorithm based on immuno-
histochemical results (IHC4) [48].
Prognostic and Predictive Factors
In the past years, the use of biomarkers and molecular tests 
has been rapidly increasing in order to provide the patients 
with the optimal personalized treatment. On the other hand, 
many of the tests are not yet sufficiently validated [56].
The nuclear antigen Ki-67 has become established as a pro-
liferation marker, although there has been a broad discussion 
on thresholds and lack of standardization. The AGO consid-
ers Ki-67 as an additional marker to further estimate the 
prognosis of EBC (LoE 1bB, AGO +) [179, 210]. In nodal-
negative EBC, proliferation markers like Ki-67 may be help-
ful in decision making (LoE 2bC, AGO +/–) [179]. In the 
 adjuvant setting in hormone receptor (HR)-positive patients 
receiving endocrine therapy alone, low Ki-67 was associated 
with good prognosis [48]. Furthermore, in adjuvant endocrine 
treatment, high Ki-67 levels (≥ 14%) may identify patients 
that particularly benefit from initial letrozole/AI treatment 
versus tamoxifen (LoE 2aB, AGO +/–) [197]. On the other 
hand, Ki-67 in the daily practice might serve as predictive fac-
tor in favor of chemotherapy in the adjuvant setting [179] 
(LoE 2aB, AGO +). Ki-67 may further predict response to 
neoadjuvant treatment [68] (refer to section ‘Neoadjuvant 
[Primary] Systemic Therapy’).
Topoisomerase II alpha (Topo IIa) gene amplification is 
a biomarker of potential usefulness in the neoadjuvant 
 treatment of breast cancer. In endocrine-unresponsive and 
HER2-overexpressing tumors, Topo IIa amplification corre-
lates  significantly with a high probability of pCR after neo-
adjuvant anthracycline-based chemotherapy [156] (LoE 2bB, 
AGO +/–).
clinical consequence (LoE 5, AGO +). If no further axillary 
dissection is planned (according to the criteria of the ACO-
SOG Z0011-trial; see section ‘Breast Cancer Surgery and 
 Oncological Aspects’) frozen sections of the excised sentinel 
node can be omitted (LoE 5D, AGO +/–) [206]. Today, tumor 
banking for research including clinical studies is getting more 
important. However, it is highly recommended to perform 
preservation of tumor tissue always in cooperation with the 
pathologist (LOE 5D, AGO +).
Pathological reporting must include tumor type and size, 
grade, tumor/node/metastasis (TNM) stage, margins in detail, 
extent of intraductal component if present, vascular invasion, 
and number of axillary lymph nodes involved, as well as ER, 
PR and HER2 expression.
Currently, Ki-67 is not recommended as a routine prognos-
tic factor, but it may be helpful in validating the grade of tu-
mors (LoE 3bB, AGO +). G1 tumors usually show a Ki-67 
index below 15% and G3 tumors exhibit a labeling index 
≥ 25%. In core biopsies, Ki-67 is better suited to predict the 
final histological grade than mitotic counts. Whether a thres-
hold of 14% is able to discriminate between luminal A and B 
type awaits further research. The analysis of the ‘International 
Ki-67 in Breast Cancer Working Group’, however, has shown 
that Ki-67 is highly sensitive to variations in methodology; 
therefore, it still cannot be recommended as standard marker 
[48, 57, 110, 126, 139, 203].
Special pathological reporting is necessary in patients 
 undergoing neoadjuvant systemic therapy (NST). There exist 
at least 5 different reporting scores for the grade of remission 
after NST; some of these, however, are only validated for 
 inflammatory breast cancer (e.g. [215]). If pathological com-
plete remission (pCR) is expected, it seems to be prognosti-
cally relevant to report exactly the type of remission in detail, 
including information about remaining DCIS in the ipsilateral 
breast and remaining tumor in the ipsilateral axillary lymph 
nodes [198].
Determination of ER and PR has still to be performed by 
IHC. Results should be reported by percentage of stained 
tumor nuclei and tumors are called ER positive if ≥ 1% of the 
tumor nuclei are stained (LoE 1aA, AGO ++). The staining 
intensity of the positive tumor nuclei may provide additional 
information. With regard to HER2 determination, only IHC 
and in situ hybridization (ISH) techniques (e.g. fluorescence 
ISH (FISH), chromogenic ISH (CISH)) are accepted (LoE 
1aA, AGO ++). Results of dual-color ISH are judged positive 
if the signal ratio is ≥ 2.0 (HER2 vs. centromer 17). Quality 
assurance evaluation showed that HER2 overexpression is ex-
pected in 16% of unselected cases of EBC [37]. However, for 
ER/PR and HER2 expression, quantitative RNA assessment 
(qt-PCR, array) is not validated to estimate therapy sensitivity 
and must not be used (LoE 2bB, AGO –) [49, 132, 141].
From expression arrays, intrinsic types of breast cancer 
were derived: HER2-enriched, basal-like types, luminal type 
A and B. Although these molecular biologically defined types 
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In nodal-negative patients with EBC, gene expression 
 analysis may support decision making in some patients 
(LoE 2b B, AGO +/–). In view of the widespread use of those 
tests, the AGO committee provides a background chart in 
which 6 frequently used molecular predictors (Mammaprint, 
Oncotype DX, Theros, MapQuant Dx, Endopredict, and 
PAM 50) are screened. The distinct indications of the diffe-
rent tests have to be taken into account [69, 17, 172, 147, 148]. 
The molecular predictors should not be used to determine the 
HR status or especially the HER2 status [49].
Breast Cancer Surgery and Oncological Aspects
Clinical assessment combined with imaging is mandatory for 
preoperative assessment of the breast tumor. Preoperative 
histopathological diagnosis should be performed by imaging-
guided percutaneous needle biopsy (e.g. core needle biopsy) 
(LoE 1cA, AGO +). The value of preoperative magnetic 
 resonance imaging (MRI) to assess the extent of breast  disease 
is still under discussion (LoE 1cB, AGO +/–). This procedure 
may result in the detection of multiple invasive foci within 
the breast that had not been identified on previous standard 
mammography and ultrasonography. The impact of these 
findings on subsequent surgical management and ultimately 
disease-free survival (DSF) remains a controversial topic.
The standard surgical procedure for EBC is BCS followed 
by RT (LoE 1aA, AGO ++). Skin-sparing mastectomy (SSM) 
with or without conservation of the nipple-areola complex is 
an oncologically safe treatment option [77, 146]. Survival rates 
of all these modern surgical procedures are at least equivalent 
to those after modified radical mastectomy (MRM).
Sentinel lymph node dissection (SLND) has become the 
standard surgical procedure in patients with clinically and 
 sonographically negative axilla (cN0). SLND allows us to 
 reliably stage patients as node positive or node negative [50, 
76, 160, 184]. Micrometastases (≤ 2 mm) in the sentinel lymph 
node are no indication for axillary dissection in clinically 
node-negative patients [72] (LoE 1baB, AGO –).The recent 
results from all SLND trials reflect that axillary dissection of 
lymph nodes may not not be necessary in patients with breast-
conserving therapy (BCT) if less than 3 sentinel lymph nodes 
are involved and the criteria of the ACOSOG study are met 
(LOE 2bB, AGO +/–). (ACOSOG criteria: The American 
College of Surgeons Oncology Group Z0011 trial, a phase III 
noninferiority trial conducted at 115 sites and enrolling pa-
tients from May 1999 to December 2004. Patients were 
women with BCT and clinical T1–T2 invasive breast cancer, 
no palpable adenopathy, and 1–2 sentinel lymph nodes con-
taining metastases identified by frozen section, touch prepara-
tion, or hematoxylin/eosin staining on permanent sections [33, 
207]). However, this is still an issue of debate since prospec-
tive studies with sufficient power are lacking [84]. If after 
thorough consideration surgeons and patients decide to omit 
axillary dissection, then irradiation of axillary lymph nodes is 
not indicated (LOE 5D, AGO –); whole-breast irradiation 
(WBI) with standard tangential fields is sufficient for local 
and regional control. However, axillary dissection remains 
mandatory in all cases with one or more involved sentinel 
lymph nodes if the inclusion criteria of the ACOSOG study 
are not met (e.g. mastectomy).
Surgery is an integral part of the neoadjuvant approach in 
breast cancer treatment. The aim of surgery after NST is to 
completely remove invasive and non-invasive breast cancer 
residues and to obtain clear margins at pathology examina-
tion. Important is the exact documentation of the tumor loca-
tion before, during and after NST (LoE 5D AGO ++). Senti-
nel node excision should be performed prior to surgical proce-
dures in order to obtain an exact staging (LoE 3bC AGO +).
After primary surgery, adjuvant treatment (systemic ther-
apy and RT) has to be started as soon as possible (LoE 1bA, 
AGO ++). Adjuvant chemotherapy should precede RT 
(LoE 1bA, AGO ++).
Plastic Reconstructive Aspects after Mastectomy
Oncoplastic surgery and breast reconstruction play an integral 
role in surgical treatment of breast cancer. In many women, 
postmastectomy breast reconstruction is essential to restore 
the body image and improve the quality of life. Timing of 
 breast reconstruction is still a controversial issue [7, 83, 153, 
177, 213]. Both options, immediate (IBR) and delayed breast 
reconstruction (DBR), are recommended on the same level 
(LoE 3bB, AG ++). Thus, the pros and cons have to be 
weighted against each other in each patient.
The main advantage of the DBR is the lack of interference 
with adjuvant procedures as chemotherapy and RT; a dis-
advantage is the loss of the skin envelope.
IBR is preferred in combination with BCS and in SSM. 
A recent Cochrane review [58] suggests, that IBR has the 
same complication rate as the delayed procedure, albeit based 
on very limited data (only 1 randomized controlled study with 
64 women was found between 2008 and 2010). There is a need 
for prospective and longitudinal outcome studies analyzing 
this question.
If the necessity of postsurgical RT (PMRT) is not known 
at the time of mastectomy and reconstruction, there is the 
possibility of a delayed-immediate reconstruction. After SSM, 
an expander is implanted until the final decision about RT 
has been made. The planned standard reconstruction is per-
formed after completion of RT or – if not necessary at all – 
immediately (LoE 3bB, AGO +/–).
In case of an SSM with IBR using silicone breast implants, 
the partially subpectoral pocket can be enlarged and secured 
by using mesh or an acellular dermal matrix [195]. However, 
2 meta-analyses have shown that immediate postmastectomy 
implant reconstruction with acellular matrix had a higher 
326 Breast Care 2012;7:322–335 Scharl/Thomssen/Harbeck
The AGO recommendations concerning ovarian protec-
tion and fertility preservation in premenopausal patients re-
ceiving adjuvant chemotherapy did not change substantially 
compared to 2011. Whereas 4 observational studies reported 
an ovarian protective effect of GnRH agonists, only 1 of 3 
 recently published randomized controlled trials (RCTs) re-
vealed a preventive effect. The ZORO study by Gerber et al. 
[78] concluded that the observed effect of GnRH agonists 
started prior to the 1st course of chemotherapy is, at its best, 
small. The study by Munster et al. [133] has not yet finished 
recruitment.
Adjuvant Endocrine Therapy  
in Postmenopausal Patients
Many updates of the well-known trials of AIs in adjuvant 
therapy have been published in 2011, confirming the current 
AGO recommendations.
Endocrine therapy is the most important systemic adjuvant 
therapy option in EBC. The EBCTCG meta-analysis in 2011, 
comprising data on the patient level of more than 20,000 pa-
tients over 15 years of observation time since randomization, 
consistently demonstrated a strong benefit with regard to re-
currence rates und mortality for patients who received 5 years 
of adjuvant tamoxifen [61]. In this meta-analysis, it was 
 further shown that endocrine therapy is only effective in ER-
positive tumors but not in ER-negative tumors [59, 61, 101]. 
However, it was independent of adjuvant chemotherapy 
application.
This data results in the following therapy recommenda-
tions: Patients with receptor-negative tumors (ER– and PR–) 
should not receive endocrine therapy (LoE 1aA, AGO ++). 
Patients with receptor-positive tumors (ER+ and/or PR+) 
should receive endocrine therapy (LoE 1aA, AGO ++). If 
chemo-endocrine therapy is indicated, endocrine treatment 
should be given sequentially after adjuvant chemotherapy 
rather than with chemotherapy (LoE 2bB, AGO ++).
With the current guidelines for receptor testing, all tumors 
with 1% or more of positive cells for ER and/or PR should be 
considered as hormone receptor positive, and the patients are 
therefore candidates for endocrine therapy [95].
The AGO Breast Committee introduced the following 
statement: Extended endocrine treatment (EAT) should be 
considered also for those patients who switched to the post-
menopausal state during 5 years of tamoxifen treatment.
Adjuvant Cytotoxic and Targeted Therapy
Recently published trials and meta-analyses actually con-
firmed the AGO treatment recommendations with regard to 
adjuvant cytotoxic and targeted therapy. There were upgrades 
in the LoE and 2 clinically relevant modifications, one 
complication rate than an expander implant, although with 
limited data for comparison [2, 105] (LoE 2b/3C, AGO +/–).
The issue of antibiotic prophylaxis remains controversial. 
In patients with postmastectomy implant reconstruction, es-
pecially after prior ipsilateral chest wall irradiation, a peri-
operative prolonged antibiosis (extended trimethoprim/sulfa-
methoxazole therapy) may be beneficial (AGO +). This was 
shown in a single-institution and single-surgeon analysis with 
51 patients undergoing implant reconstruction from 2005 to 
2008 [129].
Adjuvant Endocrine Therapy  
in Premenopausal Patients
The 2011 AGO recommendations for adjuvant endocrine 
therapy in premenopausal patients are still valid in 2012. The 
recent publication of the Early Breast Cancer Trialists’ Col-
laborative Group (EBCTCG) meta-analysis strengthened the 
evidence of a substantial reduction of recurrence and mortal-
ity rates by 5-year tamoxifen treatment of premenopausal 
ER-positive patients throughout the 15 years following rand-
omization [61]. The ER status was the only predictive factor 
[61]. AIs alone must not be given in the premenopausal situa-
tion (LoE 1cA, AGO –). First results of ongoing studies 
(SOFT, TEXT) on the combination of gonadotropin-releas-
ing hormone (GnRH) agonists with tamoxifen or AIs are ex-
pected this year.
In some instances, the assessment of the ovarian reserve 
may be important in younger premenopausal as well as in 
peri menopausal patients. In perimenopausal women under-
going treatment for breast cancer, it may be difficult to de-
termine the true menopausal status because adjuvant chemo-
therapy, tamoxifen, and GnRH analogs (GnRHa) can induce 
transient (or permanent) ovarian suppression. Measurement 
of anti-Muellerian hormone (AMH) and follicle count may 
add to the accuracy of hormone measures for determining the 
ovarian reserve (for both tests: LoE 3bB; AGO +/–).
(CRA) [175].
Fertility Preservation
Preservation of fertility is a priority in many younger women 
with EBC. Pretreatment AMH may be used to predict the 
long-term ovarian function after chemotherapy for EBC [6]. 
The antral follicle count appears to provide further knowl-
edge of ovarian function, independent of AMH and other 
 factors, e.g. follicle-stimulating hormone (FSH) or estradiol 
(E2) [176]. The antral follicle count is defined as the sum of 
follicle diameters of all follicles of ≥ 10 mm diameter in both 
ovaries [176].
Fertility preservation counseling is suggested in all patients 
who want to preserve their fertility (LoE 4C, AGO +). As-
sisted reproduction technology (ART) is an option for breast 
cancer survivors (LoE 4C, AGO +).
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Capecitabine, gemcitabine, and platinum compounds have 
been investigated in adjuvant trials. So far, none of these 
drugs can be recommended to be included into anthracycline/
taxane-based regimens. With regard to capecitabine, several 
trials could not demonstrate an additional benefit when add-
ing capecitabine to an anthracycline/taxane-based therapy 
[e.g. 103, 144] (LoE 1bA, AGO +/–). Most of the trials used 
lower doses of either the taxane or capecitabine in order to 
cope with toxicity.
Targeted Therapy
Considering targeted therapy, all studies demonstrating a 
benefit for adjuvant trastuzumab in women with HER2- 
positive tumors included node-negative and node-positive pa-
tients, and subgroup analysis showed a benefit for both groups 
of patients. Therefore, trastuzumab-containing regimens can 
be used in node-positive (LoE 1aA, AGO ++) as well as in 
node-negative patients, whenever chemotherapy is consid-
ered adequate. Women with node-negative disease, additional 
risk factors, and tumor size > 10 mm will profit from trastuzu-
mab (LoE 1aA, AGO ++). Moreover limited data from adju-
vant studies suggest that even patients with HER2-positive 
tumors smaller than 10 mm may gain benefit from trastu-
zumab [87]. Thus, the use of trastuzumab may also be consid-
ered in smaller tumors (for tumors > 5–10 mm, AGO +; for 
tumors ≤ 5 mm, AGO +/–).
In contrast to primary systemic therapy (PST), the phase 
III trials in adjuvant therapy with other targeted agents/dual 
HER2 blockade such as lapatinib, pertuzumab, and bevacizu-
mab are not yet mature (recommendation level for all 3 com-
pounds: LoE 5D, AGO –). In the TEACH trial, lapatinib was 
given in delayed adjuvant treatment, but the improvement of 
DSF (primary objective) did not reach statistical significance 
in [88] (LoE 1bB, AGO –).
Subtype-Specific Strategies
Molecular typing is based on molecular genetic testing and is 
not yet routinely available. Molecular subtypes and immuno-
histochemical surrogate markers of the tumors (HR, HER2, 
triple negative) correlate in about 70%. The differentiation of 
luminal A and B subtypes by HR status and proliferation 
markers like Ki-67 may be helpful, but a prospective valida-
tion and standardization is still lacking. As prospective evi-
dence is still pending, decision-making on chemotherapy 
based on genomic testing is not recommended outside clinical 
trials (see the following section). The current AGO expert 
opinion on treatment strategies in subtypes identified by IHC 
in a routine clinical setting is summarized in figure 1.
Neoadjuvant (Primary) Systemic Therapy
Recently published studies confirmed the benefit of NST and 
further specified its indications [51, 104, 189]. Retrospective 
 concerning trastuzumab in node-negative disease and the 
other focusing on other targeted agents (lapatinib, pertuzu-
mab, and bevacizumab). In the following, these topics are de-
scribed in the context of the main strategies in adjuvant ther-
apy of EBC.
Cytotoxic Agents and Combinations
Provided that the indication for adjuvant chemotherapy is 
given, anthracycline-based combination chemotherapy is re-
garded as minimum standard treatment (LoE 1aA, AGO ++). 
As shown in a meta-analysis, these regimens provide an addi-
tional reduction of relapse rate (ratio 0.89, p = 0.0001) and 
mortality (ratio 0.84, p < 0.001) compared with adjuvant CMF 
therapy (cyclophosphamide, methotrexate, and 5-fluorour-
acil) after 15 years [59].
In general, by adding taxanes, DSF and overall survival can 
be further improved (LoE 1aA, AGO ++) and eventually side 
effects, particularly cardiotoxicity, can be reduced. The corre-
sponding relative risk reduction is rather dependent on the 
tumor biology than on the nodal status and extent of disease 
[62].
In node-positive disease, dose-dense (q2w) adjuvant 
chemo therapeutic schedules may improve the relapse-free 
and overall survival compared to conventional adjuvant treat-
ment options [22, 40, 130] (LoE 1aA, AGO ++). High-dose 
chemotherapy with autologous stem cell support is not recom-
mended as adjuvant treatment in breast cancer (LoE 1aA, 
AGO –) [19].
The efficacy of CMF versus no chemotherapy has been 
shown in numerous trials with a long-term follow-up of mean-
while up to 20 years, and has been proven in meta-analyses 
(e.g. [62], EBCTCG 2012). Therefore, 6 cycles of CMF can be 
given in patients with contraindications for anthracycline- and 
taxane-containing regimens [21]. Still, in patients with a risk 
profile indicating a need for adjuvant chemotherapy, giving 
CMF is better than giving no therapy (LoE 1aA, AGO ++).
Fig. 1. Subtype-specific general adjuvant strategies.
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were also active in a small subgroup of HER2-positive breast 
cancers. However, criteria to select patients for this approach 
are lacking [34, 82] (LoE 2bB, AGO +/–).
In patients with HER2-negative breast cancer, 2 large 
 randomized phase III studies showed a higher pCR rate with 
neoadjuvant chemotherapy plus bevacizumab than with 
chemotherapy alone, but survival data are still lacking and 
subgroup analyses showed inconsistent results [15, 75, 201]. In 
the German GeparQuinto trial, bevacizumab significantly in-
creased the pCR rate in the triple-negative subgroup, while 
no effect was seen in HR-positive patients [75, 201]. In the 
NSABP B40 trial, however, the effect of bevacizumab was 
seen predominantly in HR-positive breast cancer patients [15] 
(for both subgroups: AGO +/–).
Tumor response to NST is evaluated by clinical examina-
tion or ultrasound or mammography. In case of early response 
following 2–4 courses (6–12 weeks) of an anthracycline- 
containing NST, the AGO Breast Committee recommends 
to complete NST as planned for at least 18 weeks in accord-
ance with Kaufmann et al. [104] (LoE 1bA, AGO ++). In 
 patients with HR-positive tumors responding to 2 cycles of 
docetaxel, adriamycin, cyclophosphamide (DAC), however, 
continuation of treatment with 6 instead of 4 cycles of DAC 
significantly improved DFS and overall survival. In a retro-
spective subgroup analysis, this benefit was confined to 
 patients with HR-positive breast cancer [199] (LoE 2baC, 
AGO +).
In patients with no early response to NST (no change), 
completion of chemotherapy as planned is recommmended 
(LOE 2bC, AGO ++). An alternative option is continuation 
of NST with a non-cross-resistant regimen, as is 4 cycles of 
paclitaxel or docetaxel following 4 cycles of adriamycin-cyclo-
phosphamide (LOE 2bB, AGO +). In case of no change to 
2 cycles of DAC, the switch to 4 cycles of vinorelbine plus 
capecitabine also improved survival (LOE 1bB, AGO ++).
In case of progressive disease, stop of PST and immediate 
surgery or RT is recommended (LOE 4D, AGO ++). Addi-
tional adjuvant chemotherapy with a non-cross-resistant regi-
men may be considered (LOE 4D, AGO +/–).
Another important objective of NST is reduction in tumor 
volume, thus making BCT feasible. BCT should not be consi-
dered if negative margins are not achievable even after repeti-
tive excisions [104] (LoE 3bC, AGO –). BCT is further not 
indicated in case of widespread DCIS or microcalcifications 
(AGO –) and should not be considered if adjuvant RT is not 
feasible [104] (AGO –).
In inflammatory breast cancer, BCS is not recommended, 
even if clinically complete response has been achieved (LoE 
2bC, AGO –); in case of pCR, however, BCT may be consid-
ered although data are scarce (AGO +/–). Selected patients 
with multicentric lesions (lesions in different quadrants) or 
cT4a–c tumors who achieved a clinically complete response 
with NST had good outcome following BCT in small retro-
spective analyses. However, BCT is not recommended in 
analyses of subgroups defined by clinico-pathological para-
meters added to the knowledge of prognostic and predictive 
factors. In particular, recommendations emerged regarding 
modifications of cytotoxic regimens in cases of early or no 
early response to NST.
The achievement of pCR following NST is associated with 
improved survival [80, 109, 186, 198, 199]. Retrospective 
 analyses suggested that this association is mainly confined to 
specific subgroups, in particular to triple-negative, HER2- 
positive (non-luminal) and luminal B (HER2-negative) breast 
cancer [66, 199].
According to a meta-analysis that included 3332 patients 
treated in 7 German neoadjuvant trials, clinico-pathological 
factors predicting pCR following NST are younger age, 
smaller tumor size, non-lobular histology, higher grade, nega-
tive HR status, triple-negative, and HER2-positive status 
[43, 100, 200]. Considering subgroups, higher probability of 
pCR was associated with (1) longer treatment duration in 
HR-positive tumors, (2) higher doses of anthracyclines in 
HER2-negative tumors, (3) short-term higher doses of 
 taxanes and anthracyclines in triple-negative tumors, and (4) 
trastuzumab-containing treatments in HER2-positive tumors 
[200].
Though results of exclusively retrospective studies evaluat-
ing gene expression signatures as prognostic and predictive 
parameters are promising, so far none of these signatures has 
been proven to be of sufficient discriminatory power to be 
used in the clinical setting [70] (LoE 2bC, AGO +/–).
Outside clinical trials, the same regimens that are recom-
mended in the adjuvant setting should be used for NST, i.e. 
anthracycline- and taxane-containing regimens for 18–24 
weeks [104] (LoE 1aA, AGO ++). If adjuvant chemotherapy 
is indicated, the identical treatment can be applied in the neo-
adjuvant setting with similar DFS and overall survival, even 
over a follow-up period of 16 years [158]. Recommended regi-
mens are those that were used in the superior treatment arms 
of large randomized neoadjuvant trials (NSABP B-27, Gepar-
Duo, GeparTrio, ECTO).
A short dose-dense chemotherapy regimen with epirubicin 
and paclitaxel increased the pCR rate and survival as com-
pared to 4 cycles of standard dose epirubicin plus paclitaxel 
[187]. A sufficiently long NST with dose-intensified epirubicin 
and paclitaxel followed by CMF, however, increased only the 
pCR rate but not the DSF as compared to standard treatment 
[185, 190] (LoE 1bB, AGO +/–).
Trastuzumab should be provided to all patients with 
HER2-overexpressing breast cancer and no contraindications 
(LoE 1bA, AGO ++) [29, 80, 81, 154, 188]. The dual anti-
HER2 treatment strategy with trastuzumab and lapatinib 
(AGO +/–) or trastuzumab and pertuzumab (AGO +/–) in 
combination with chemotherapy can significantly increase the 
pCR rate compared to a single anti-HER2 regimen. Survival 
data, however, are not available so far [12, 82, 91, 164]. 
Chemo therapy-free regimens combining 2 anti-HER2 agents 
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data from RCTs are convincing and gave reason for a change 
in recommendations [96, 209]. In the update 2012, the AGO 
Breast Committee states that hypofractionation schedules in 
WBI should be considered in selected patients (LoE 1aB, 
AGO +).
The recommendation is in part based on new evidence re-
sulting from a systematic review of the Cochrane Collabora-
tion [102]. Reviewing the data of RCTs dealing with hypofrac-
tionated RT, the authors substantially altered their conclusion 
of the last review from 2008, stating: ‘Two new studies have 
been published since the last version of the review, altering 
our conclusions. … We have evidence from four low to me-
dium quality randomized trials that using unconventional 
fractionation regimens (greater than 2 Gy per fraction) does 
not affect local recurrence, is associated with decreased acute 
toxicity and does not seem to affect breast appearance or late 
toxicity for selected women treated with BCT. These are 
mostly women with node negative tumors smaller than 3 cm 
and negative pathological margins’ [102].
Four trials, involving 7095 women, were included in the 
 review. Local recurrence was not significantly different for 
women having fewer treatments. Most of the women in the 
trials (89.8%) had tumors less than 3 cm in size, all had 
 complete removal of the tumor on pathology and 79% had no 
evidence of cancer in their lymph nodes. Where the breast 
size was known, 87% had small or medium breasts. This up-
dated Cochrane Collaboration review indicates that for 
women who fit these criteria, using fewer radiation treatments 
after tumor removal is a safe and effective option [102].
Additionally, hypofractionated RT schemes are further 
recommended/considered in several updated international 
guidelines (Belgian KCE 2010, French guidelines 2010, 
NCCN 2011, NICE 2010).
Nevertheless, caution is still warranted because long-term 
follow-up (> 5 years) is available for only a small proportion 
of the randomized patients (Canadian study [207]).
Longer follow-up is required for a more complete assess-
ment of the effect of altered fractionation [102].
Accelerated Partial Breast Irradiation
The AGO Breast Committee did not change the recommen-
dations concerning accelerated partial breast irradiation 
(APBI) as a prior (‘anticipated’) or postoperative boost RT 
(LoE 1aA, AGO +) [183]. Growing evidence suggests that 
APBI alone may be able to sufficiently reduce the risk of 
local relapses in selected patients. On the other hand, APBI 
as sole therapy still remains an experimental approach due 
to the lack of results from long-term follow-up of RCTs 
(LoE 1bC, AGO –). Thus, partial breast irradiation should be 
performed as part of prospective trials. Partial breast irradia-
tion can be delivered using interstitial, intracavitary, external-
beam or intraoperative techniques (IORT) (for details see 
www.ago-online.de).
these cases as a routine procedure outside controlled clinical 
trials, but may be an option in individual cases (AGO +/–) 
[51, 104].
Adjuvant Radiotherapy
EBCTCG Update 2011
Postoperative RT is known to substantially reduce the risk of 
local and regional breast cancer relapse, both when given 
after mastectomy (MRM) and after BCS. The recently pub-
lished update of the EBCTCG analysis clearly demonstrates 
an overall survival benefit due to adjuvant RT after BCS (15-
year gain 3.8% with RT for all patients, 3.4% in pN0 and 
8.5% in pN+ patients) [60]. Absolute decrease in the risk of 
relapse of 16% (19% vs. 35%) resulted in an absolute de-
crease of 4% (21% vs. 25%) in the risk of dying from breast 
cancer [27]. RT led to a proportional reduction of 50% in 
overall recurrence (referring mainly to locoregional recur-
rences), thus exceeding that from chemotherapy or endocrine 
therapy alone [27]. In 2009, similar analyses were published 
from the Surveillance, Epidemiology and End Results 
(SEER) and the UZ Brussels databases [204].
Even in patients with invasive breast cancers and presum-
ably favorable prognostic factors (tumor size < 1 cm, ER posi-
tivity, no ipsilateral lymph node involvement, low grading), 
ipsilateral breast cancer recurrence after BCS occurs fre-
quently enough to justify postoperative irradiation, regardless 
of adjuvant systemic endocrine treatment [1, 41, 59, 60, 121, 
209].
In the EBCTCG update 2011 concerning adjuvant RT in 
breast cancer patients after BCS, the ‘4:1 relation’ was con-
firmed: For every 4 recurrences avoided by year 10, about 1 
breast cancer death is avoided by year 15 [27, 60]. The same 
relation has been seen before in breast cancer patients with 
RT after mastectomy [27].
To obtain the advantages of adjuvant RT, the use of 
 modern techniques in RT planning and delivery is mandatory.
WBI and Hypofractionation
WBI should be systematically applied after BCS (LoE 1aA, 
AGO ++). The total dose should be equal or equivalent to 
50 Gy in 25 fractions over 5 weeks. RT of the breast in addi-
tion to BCS reduces the risk of relapse in all patient sub-
groups and is strongly recommended in the updated guide-
lines of the National Comprehensive Cancer Network 
(NCCN) USA (2012), the National Institute for Health and 
Clinical Excellence (NICE) CG80 (2009), the Belgian Health 
Care Knowledge Centre (KCE) (2010), the New Zealand 
Guidelines Group (2009), and the French Expert Review 
Board (2011) [16, 32, 135, 136, 138].
Although the issue of fractionation of RT of the whole 
breast is still subject of discussion in international societies of 
radiation oncology, regarding hypofractionated WBI, new 
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Carcinoma of Unkown Primary
RT of the ipsilateral breast may be considered if axillary 
 metastases are detected in patients suffering from carcinoma 
of unkown primary (CUP) with inconspicious MRI of the 
breast (LoE 3bC, AGO +/–). 48 patients with negative MRI 
results were included into a non-randomized study; herein, 
73% were treated with radiation and 27% were observed. 
After a  median follow-up of 68 months, recurrence-free 
 survival was shown in 84% patients with RT versus 34% with-
out (p < 0.001) [11].
Phyllodes Tumor and Paget’s Disease
Recommendations for malign phyllodes tumor as well as 
Paget’s disease did not undergo any changes due to lack of 
new data and clinical trials.
Sarcoma (Angiosarcoma) of the Breast
Current data show that in sarcoma, particularly angiosarcoma, 
not the type of surgery but the size of the tumor, grading, and 
especially adequate safety margins are decisive prognostic 
factors (LoE 4C, AGO ++). Angiosarcoma is a serious  disease 
that can occur 10–15 years after RT. BCS may be performed 
under the condition that large safety margins are feasible and 
the patient has given her informed consent in view of the 
 associated risk (LoE 4C, AGO +/–) [4, 205]. Diagnosis should 
be obtained by core biopsy (LoE 4D, AGO ++), not fine- 
needle biopsy (LoE 4D, AGO –) [119]. After surgery, anthra-
cycline-based chemotherapy and RT might be considered, 
particularly in high-risk cases (LoE 4C, AGO +/–) [10]. In 
metastatic disease, paclitaxel as well as liposomal doxorubicin 
should be given, particularly in patients with angiosarcoma. 
After treatment failure with anthracycline and ifosfamide, 
 trabectedin can be offered to patients suffering from leio-
myosarcoma (LoE 2bB, AGO +) [165].
New Aspects in Therapy Side Effects
Bisphosphonates and Denosumab
In terms of toxicity, bisphosphonates and denosumab seem to 
be similar (e.g. [174]). In patients with advanced breast cancer 
receiving bisphosphonates and denosumab, the rates of ad-
verse events (AEs) and serious AEs were similar. Osteo-
necrosis of the jaw (ONJ) occurred infrequently (2.0% deno-
sumab; 1.4% zoledronic acid; p = 0.39); however, patients 
should be informed about this specific risk [174]. In a recently 
published pooled analysis of 3 randomized phase III trials of 
denosumab versus zoledronic acid in patients treated for 
MBC, the occurrence rate of ONJ for denosumab was con-
firmed with 1.67% [191].
Radiotherapy of the Axilla
The AGO recommendations regarding RT of the axilla have 
been modified in view of the corresponding recommendations 
for axilla surgery. If in case of positive sentinel lymph nodes 
axillary lymph node dissection (ALND) is not performed in 
compliance with the recommendations stated in the section 
‘Breast Cancer Surgery and Oncological Aspects’, WBI with 
standard tangential fields might be sufficient for local and 
 regional control; additional separate RT of the axilla may be 
harmful and is not indicated [194] (LoE 2aB, AGO –).
Internal Mammary Chain Radiotherapy
Important prospective data suggested that internal mammary 
chain RT would not be necessary, even in cases of internal or 
central tumor locations, or in patients with positive axillary 
lymph nodes. These data warrant confirmation. The indica-
tions for internal mammary chain RT should be carefully 
 balanced against potential toxicity (LoE 2bC, AGO +/–). 
High-quality techniques should be used for decreasing the 
dose delivered to the heart [8].
Specific Situations in Breast Cancer
Older Patients
Increasing evidence suggests that axilla dissection can be 
omitted in case of small tumors and clinically negative axilla 
(LoE 2bC, AGO +). Recently, Martelli et al. [122] presented 
the update of a study including 671 patients ≥ 70 years (172 
with axilla dissection and 499 patients without). After a me-
dian follow up of 15 years there was no significant difference 
in mortality rates in patients with pT1 cN0 disease with 
and without axilla dissection, respectively (10.7% vs. 10.7%, 
p = 0.836).
Inflammatory Breast Cancer
Prospective randomized studies in patients with inflammatory 
breast cancer are still missing. Current updates are focusing 
on the definition that demands definitive diagnosis of invasive 
carcinoma and clinical signs of skin affection (> 1/3 of the 
breast involved, in contrast to the previous definition of > 2/3 
involvement) [51]. Biopsies of the skin should be obtained for 
diagnostic reasons (LoE 2cB, AGO +), yet only with a detec-
tion rate of < 75%. The use of trastuzumab as neoadjuvant 
treatment option for inflammatory breast cancer (LoE 2bB, 
AGO ++) is further supported by the current data of the 
NOAH study [166]. In inflammatory breast cancer, BCS is not 
recommended, even if a clinically complete response is 
achieved by neoadjuvant chemotherapy (LoE 2bC, AGO –); 
in case of pCR, however, BCS may be considered, although 
data are scarce (AGO +/–). [51, 104].
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Bevacizumab
Recently published systematic reviews are corresponding with 
toxicity data of randomized trials with bevacizumab plus 
 chemotherapy. In an open-label, randomized, phase III trial, 
the efficacy and safety of paclitaxel plus bevacizumab was 
compared with that of paclitaxel alone in patients with MBC. 
Severe AEs were more frequent in patients who received pa-
clitaxel plus bevacizumab than in the paclitaxel alone group: 
grade 3 or 4 hypertension (14.8% vs. 0.0%, p < 0.001), pro-
teinuria (3.6% vs. 0.0%, p < 0.001), headache (2.2% vs. 0.0%, 
p = 0.008), and cerebrovascular ischemia (1.9% vs. 0.0%, 
p = 0.02). Infection was more common (9.3% vs. 2.9%, 
p < 0.001) in patients receiving the combination, but febrile 
neutropenia was uncommon (< 1% overall) [128].
A systematic review and meta-analysis of 5 randomized 
phase III clinical trials that used bevacizumab alone or in 
combination with chemotherapy in MBC showed a statisti-
cally significant bevacizumab-associated increased risk for 
proteinuria (odds ratio (OR) = 27.68), hypertension (OR 
= 12.76), left ventricular dysfunction (OR = 2.25), and hemor-
rhagic events (OR = 4.07), while no increased incidence was 
found for gastrointestinal perforation, vascular or fatal events 
and febrile neutropenia [44] (for a review of side effects see 
also [94]). However, careful selection of patients for this 
 therapy seems to be reasonable.
Bisphosphonates and RANKL Antibody Denosumab
Bone health and thus osteooncology is gaining increasing im-
portance in the management of breast cancer patients. New 
data have been published in 2011 for bisphosphonates and 
 denosumab resulting in changes in current AGO recommen-
dations [183].
In adjuvant treatment, bisphosphonates can be recom-
mended with a high level of evidence for the treatment and 
prevention of cancer-related loss in bone mineral density 
(BMD) (LoE 1bB, AGO ++). BMD should be measured re-
gularly (LoE 2bB, AGO +). Besides physical activity, avoid-
ing a body mass index (BMI) < 20 kg/m2, sufficient calcium 
intake, and vitamin D supplementation, the reduction of 
smoking is recommended (LoE 4C, AGO ++).
The RANK ligand (RANKL) antibody denosumab can be 
considered as promising alternative to bisphosphonates in the 
treatment of osteoporosis (LoE 1bA, AGO ++) [47]. Deno-
sumab, however, is not yet licensed for the prevention of bone 
loss in breast cancer patients (LoE 1bB, AGO +), although 
data is available. The effect of denosumab on BMD was eval-
uated in women receiving adjuvant AIs. After 24 months, the 
lumbar spine BMD increased by 7.6%, the hip BMD by 4.7%, 
and the distal radius by 6.1% [63, 64]. Ongoing studies cur-
rently evaluate this effect in the adjuvant setting.
With regard to prevention of metastases, bisphosphonates 
(clodronate 1600 mg/day p.o. or zoledronic acid 4 mg, q6m, 
i.v.) are indicated in specifically defined subgroups of patients 
(LoE 1bB, AGO +) [42, 52, 86, 150]. In an update of the 
ABCSG-12-trial, zoledronic acid significantly improved DFS 
(hazard ratio (HR) 0.71; 95% confidence interval (CI) 0.55–
0.92; p = 0.011) [86].
In postmenopausal women on adjuvant treatment with 
zoledronic acid and letrozole, the 5-year results of the ZO-
FAST study revealed a continuous increase of the BMD and 
an improvement of the DFS by 34% [52]. Furthermore in a 
subgroup analysis of the AZURE study, the DFS increased in 
postmenopausal women (HR 0.75; 95% CI 0.59–0.96; p = 
0.02) as well as the overall survival (HR 0.74; 95% CI 0.55–
0.98; p = 0.04) [42]. Bisphosphonates, however, are not yet li-
censed for the prevention of metastases.
To date, bisphosphonates are the current standard in the 
therapy of patients suffering from breast cancer-related bone 
metastases (LoE 1aA, AGO ++). In the registration trial, 
 Stopeck et al. [174] demonstrated a significant advantage of 
denosumab (120 mg s.c., q28d) compared to zoledronic acid 
(4 mg i.v., q28d) regarding the time to occurrence of a skele-
tal-related event (SRE) (HR 0.82; p = 0.0096). The time 
 period until the occurrence of moderate and severe pain could 
be prolonged from 176 to 295 days (p = 0.0024).
The results were confirmed through integrated analyses of 
3 denosumab pivotal trials [115]. The time period to the re-
occurrence of events was prolonged. Additionally, the type of 
SRE, for example the reduction of pathological fractures or 
the necessity of RT, showed consistent results [85]. Thus, the 
application of denosumab is a promising alternative for the 
reduction of SRE (LoE 1aA, AGO ++) as well as for the pro-
longation of the time period to the occurrence of bone pain 
(LoE 1bA, AGO ++).
Before starting the treatment with bisphosphonates or de-
nosumab, the women should be informed on possible un-
wanted side effects. Furthermore, due to the risk of ONJ in 
the range of 1.3–1.8% (LoE 1b), the patients should be of-
fered a complete dental examination and, if necessary, oral 
restorative and rehabilitation therapy (LoE 1b).
Supportive Care
There have been no clinically relevant changes in the AGO 
recommendations compared to 2011. Managing breast cancer 
with highly effective cytotoxic therapies, it is essential to 
 recognize febrile neutropenia, which is defined by the follow-
ing criteria: oral temperature > 38.5 °C or 2 consecutive 
 readings > 38 °C within 2 h in a patient with an absolute 
 neutrophil count (ANC) < 500 cells/ml or expected to fall 
below 500 cells/ml. Thorough baseline clinical examination 
and daily clinical evaluation is mandatory (LoE 5D AGO ++). 
Alhough in general patients should be hospitalized (LoE 1bA 
AGO++), some low-risk patients may be treated also by 
homecare (LoE 1bA AGO +). Routinely, differential blood 
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 lymphovascular space invasion (LVSI), higher grading, ER 
negativity, and close margins [149].
Isolated IBTRs following BCT have a better prognosis 
with regard to overall survival probability (5-year overall 
 survival: 65%) than chest wall recurrences following mastec-
tomy (5-year overall survival: 50%). If the supraclavicular 
fossa is additionally affected, the overall survival probability 
decreases (3-year overall survival: 49%) [159].
The analyses also showed that patients with early recur-
rence had an impaired survival probability whilst in patients 
with late recurrences survival probability is not affected [113].
There are no studies that confirm an implication of the 
 re-staging findings in systemic treatment or improvement of 
overall survival of asymptomatic patients with resectable 
 locoregional recurrence. Nevertheless, to avoid ‘over- or 
 undertreatment’ and to prevent complications, the AGO 
 recommends re-staging in all patients with locoregional recur-
rences as in 2011 (LoE 5D, AGO ++).
Endocrine Therapy in MBC
Hormonal therapy remains the treatment of first choice 
for metastatic patients with endocrine-responsive breast 
 cancer (LoE 1a A, AGO ++). The sequential use of the avail-
able drugs depends on the individual pretreatment. Reassess-
ment of ER, PR, and HER2 in tumor tissue at the time of 
 diagnosis of relapse is recommended whenever possible, in 
order to prove metastatic disease and to better tailor treat-
ment. In a prospective analysis, therapeutic management 
for 1 of 6 patients was changed after reassessment of metas-
tases [182]. However, it has not yet been investigated whether 
the efficacy of treatment is superior if it would be guided by 
the new ER, PR or HER2 status of the current metastasis 
rather than if it is based only on the findings of the primary 
tumor.
Fulvestrant plays an increasing role in the treatment of 
MBC. In addition to the approved dose of 250 mg by intra-
muscular injection, a high-dose (HD) regimen of fulvestrant 
(500 mg once a month plus 500 mg on day 14 of month 1) is 
associated with a significantly longer progression-free survival 
(PFS) and can be recommended for patients who had pro-
gressed on prior endocrine therapy (LoE 1bA, AGO +). 
Based on currently available data, HD fulvestrant appears to 
be as well tolerated as standard fulvestrant. However, no sur-
vival benefit was shown [46, 98].
In 707 patients with HR-positive disease, first-line endo-
crine treatment with anastrozole was compared to the combi-
nation of anastrozole and fulvestrant. Fulvestrant doses were 
500, 250 and 250 mg at start and after 14 and 28 days, respec-
tively. Thereafter, fulvestrant was given with 250 mg every 
4 weeks. For the whole study population, PFS (13.5 vs. 
15.0 months; HR 0.80; 95% CI 0.68–0.94; p = 0.007) and over-
all survival (41.3 vs. 47.7 months; HR 0.81; 95% CI 0.65–1.00; 
cell count, blood cultures, and lung imaging have to be per-
formed. Antibiotic therapy has to be initiated immediately 
based on empirical efficacy (LoE 1aA AGO ++) – and 
 adjusted later. In case of failure of antibiotic therapy, empiri-
cal antifungal therapy must also be initiated for 4–7 days 
(LoE 1bA AGO ++). Application of granulocyte colony- 
stimulating factor (G-CSF) is a matter of debate (LoE 2b B 
AGO +/–).
Breast Cancer Follow-Up
While there were no clinically relevant modifications in the 
existing AGO recommendations for breast cancer follow-up, 
in 2012 new statements were included concerning LCIS and 
DCIS. Women with LCIS and DCIS have an elevated risk for 
breast cancer. Thus risk communication should provide 
women with information of risk reduction strategies (e.g. 
 follow-up schedule and medical intervention). Follow-up of 
women with LCIS or DCIS comprises interval history, phy-
sical examinations and counseling every 6–12 months for 
5 years, and then annually. A diagnostic mammography 
should be performed yearly. In patients undergoing BCT for 
invasive breast cancer, the first ipsilateral follow-up mammo-
gram should be performed 6–12 months after the completion 
of breast-conserving RT) [136].
Locoregional Recurrence
The AGO recommendations for locoregional recurrence did 
not change substantially in 2012 as compared to 2011. Some 
trials and systematic reviews that were published in 2011 add 
to the knowledge about risk factors.
About 10% (2–20%) of patients who underwent BCT will 
subsequently develop ipsilateral breast tumor recurrence 
(IBTR). Chest wall recurrences after mastectomy and isolated 
axillary recurrences are relatively rare events. Risk factors for 
IBTR include tumor size, nodal status, ER status, young age, 
positive microscopic margins, higher grading, vessel invasion, 
an extensive intraductal component, and lymphatic vessel in-
vasion. Systemic treatment and RT significantly reduced local 
recurrence. HER2 positivity emerged as an independent risk 
factor in addition to ER and PR negativity, basal-like and 
 triple-negative tumors [30, 118, 192].
Although the local outcome following salvage therapy is 
quite good, the risk of distant metastases for patients with 
local recurrence is 3–5 times higher than for those without re-
currence. The patients with locoregional recurrence survived 
almost significantly better than those with distant recurrence. 
The interval between primary diagnostics and recurrence cor-
related positively with overall survival after a recurrence 
[113]. The risk of distant metastases/impaired survival was 
 increased if ≥ 2 factors of the following were positive: 
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 eribulin may also be beneficial after failure of anthracyclines 
and taxanes.
In a recent open-label phase III trial (n = 762) [45], eribulin 
mesylate, a non-taxane microtubule inhibitor, was compared 
to treatment of physician’s choice (TPC). Overall survival was 
significantly improved in women assigned to eribulin (median 
13.1 months compared with TPC (10.6 months; p = 0.041) 
(LoE 1bB, AGO ++). The most common AEs in the eribulin 
group were asthenia or fatigue, neutropenia, and peripheral 
neuropathy.
Ixabepilone is active in anthracycline- and taxane-pre-
treated patients [131]. A recent phase III study demonstrated 
that the addition of ixabepilone to capecitabine is associated 
with increased response rates and PFS compared with cape-
citabine alone [181]. Yet, this benefit was achieved at the ex-
pense of increased toxicity, particularly sensory neuropathy 
and neutropenia. Moreover, ixabepilone is not registered for 
MBC in Germany (LoE 1bB, AGO –).
Specific Situations and Sites of Metastases
New data from recent studies and systematic reviews in 2011 
substantially confirmed the AGO recommendations.
In metachronous or primary MBC, management focuses 
on systemic therapy. The impact of local treatment on overall 
survival is still under discussion. With regard to surgery or RT 
for the primary tumor, however, retrospective data on more 
than 30,000 women from North America and Europe have 
now been published, showing a robust association between 
those procedures and prolonged survival [151]. The question 
remains whether this association reflects a selection of women 
with good prognosis [157]. There are also reports that could 
not find an advantage in overall survival after local surgery in 
this situation [55]. The AGO considers mastectomy or local 
excision of the primary tumor as an option for selected pa-
tients (AGO +/–). Axilla surgery is only indicated in patients 
with bulky axillary disease.
In distant metastases, surgery should be in general consid-
ered in patients with a good health condition, oligometastases, 
and a long distance between primary treatment and the occur-
rence of metastases [140, 163]. Reported improved overall 
survival might be the result of patient selection. Before sur-
gery is done, metastases should be confirmed by histology [23] 
(LoE 3B, AGO +). After surgery, local and systemic treat-
ment according to guidelines should be considered. Other in-
dications for surgical intervention are symptoms like persist-
ing pain or exulceration after systemic treatment (LoE 5D, 
AGO +/–).
Resection of liver metastases should only be performed if 
R0 resection is feasible and no extrahepatic metastases are 
present [18, 38, 99, 120] (LoE 3bC, AGO +/–). Other proce-
dures like regional RT as well as thermoablation are indicated 
in individual cases (AGO +/–). Mostly a survival benefit for 
p = 0.049) were statistically superior in favor of the combina-
tion therapy versus anastrozole alone. Unplanned analysis by 
prior tamoxifen suggested benefit only in the tamoxifen-naive 
group [125].
Everolimus and exemestane was compared to exemestane 
and placebo (randomly assigned in a 2:1 ratio) in 724 post-
menopausal women with HR-positive advanced breast cancer 
who progressed while receiving previous therapy with a 
non steroidal AI in the adjuvant setting and/or advanced dis-
ease. Overall response (0.4 vs. 9.5%; p < 0.001) and clinical 
benefit rate were significantly higher in the combination 
group versus exemestane alone. Further, the median PFS was 
significantly increased with the combination both by local 
(2.8 vs. 6.9 months; HR 0.43; 95% CI 0.35–0.54; p < 0.001) and 
central assessment (4.1 vs. 10.6 months; HR 0.36; 95% CI 
0.27–0.47; p < 0.001). Data on survival is immature. The com-
bination therapy was associated with a higher incidence of 
AEs than with exemestane alone. The AEs observed with 
everolimus plus exemestane included stomatitis, fatigue, 
pneumonitis, diarrhea, pyrexia, and hyperglycemia [13]. The 
data are convincing, such that the combination exemestane/
everolimus may be used in some patients as second-line endo-
crine treatment (LoE 1bA, AGO +). No changes and modifi-
cations of the current recommendations compared to 2011 
have been made for premenopausal, HR-positive, HER2-neg-
ative women and for postmenopausal, HR-positive, HER2-
positive patients.
Cytotoxic Therapy in MBC
In palliative therapy after anthracycline treatment, taxanes 
are the most commonly used compounds. A Cochrane analy-
sis demonstrated a modest survival advantage of taxane-based 
versus non-taxane regimens in this situation [79].
Nanoparticle albumin-bound paclitaxel (nab-paclitaxel) 
has demonstrated significant activity in MBC. A phase III 
trial showed higher response rates and time to progression of 
nab-paclitaxel compared with paclitaxel (175 mg/m2 over 3 h 
every 21 days) [90]. Nab-paclitaxel was associated with a 
lower risk of hypersensitivity reactions, less grade 4 neutro-
penia, but increased grade 3 sensory neuropathy. Recently, 
a phase II randomized study showed longer PFS of nab-pacli-
taxel compared with docetaxel [89]. The AGO recommenda-
tion for its use in second-line treatment was strengthened 
(LoE 2bB, AGO ++). However, neither docetaxel nor nab-
paclitaxel has demonstrated superiority over the weekly 
 schedule of paclitaxel [89].
There are few effective treatment options available to 
women with MBC who failed to respond or relapsed after 
 receiving both anthracyclines and taxanes. Several agents, in-
cluding capecitabine, vinorelbine, gemcitabine, epothilones, 
and platinum salts, as well as combinations of these, have 
been investigated [145]. Re-challenge with taxanes [93] or 
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point PFS [14]. Median PFS was 18.5 months in the pertu-
zumab group versus 12.4 months in the control group (HR 
for progression or death 0.62; 95% CI 0.51–0.75; p < 0.001). 
Interim analysis of overall survival showed a trend in favor 
of pertuzumab. There was no increase in left ventricular 
 systolic dysfunction; the rates of febrile neutropenia and di-
arrhea grade ≥ 3 were higher in the pertuzumab group. This 
new combination expands the choice of possible treatment 
options based on trastuzumab (LoE 1bA, AGO +). Since per-
tuzumab is still not approved, study participation is strongly 
recommended.
Everolimus plus Exemestane
Data of a recently published randomized phase III trial 
showed that everolimus combined with exemestane improved 
PFS in patients with HR-positive advanced breast cancer 
 previously treated with nonsteroidal AIs compared to 
 exemestane alone [13].
Resistance to endocrine therapy in breast cancer is associ-
ated with activation of the mammalian target of rapamycin 
(mTOR) intracellular signaling pathway. The mTOR inhibi-
tor everolimus added to endocrine therapy may enhance anti-
tumor activity. Included in the trial were 724 patients with 
HR-positive advanced breast cancer who had recurrence or 
progression while receiving previous therapy with a non-
steroidal AI in the adjuvant setting or in advanced disease. 
Median PFS (primary endpoint) was 10.6 months with 
everolimus and exemestane versus 4.1 months in the control 
group (HR 0.36; 95% CI 0.27–0.47; p < 0.001). The AGO level 
of recommendation is LoE 1bB, AGO +; yet, study participa-
tion is recommended.
Bevacizumab Combination Treatment
Another treatment option in MBC is to target the vascular 
endothelial growth factor (VEGF). The diverse regimens 
were re-evaluated by the AGO experts. In first-line treatment 
in HER2-negative MBC, the combination of bevacizumab 
and paclitaxel was equally well recommended (LoE 1bB, 
AGO +) as the regimen bevacizumab plus capecitabine (LoE 
2bB, AGO +) [25, 128, 162, 169].
Complementary Therapy, Hormonal Treatment,  
and Alternatives for Breast Cancer Survivors
This year’s update sees quite a few substantial modifications 
as compared to the 2011 version. They were brought about by 
a number of relevant publications, and particularly the publi-
cation of several important Cochrane reviews.
It has now been shown that prophylactic lymph drainage 
as an adjunct to guideline-conform care including physical 
therapy (exercise) has no significant impact on the short-term 
development of arm lymph edema following breast and axil-
lary surgery [54] (LoE 1a B, AGO –).
surgery or other ablation techniques has been reported. 
 However, this might be the result of patient selection.
For proven pulmonary metastases, the level of evidence for 
a curative approach is low, but some patients might benefit 
from metastasectomy followed by an appropriate systemic 
treatment (e.g. [111]) (LoE 3bC, AGO +/–). In accordance 
with the treatment of liver metastases, resection of lung 
 metastases should only be performed if R0 resection is feasi-
ble and if histological verification was done. Other procedures 
like thermoablation are indicated in individual cases (LoE 
3bC, AGO +/–).
Bone Metastases
There were no clinically relevant changes compared to 2011 
except for new data and new recommendations with regard to 
the treatment with bisphosphonates and denosumab (see sec-
tion ‘Bisphosphonates and RANKL Antibody Denosumab’).
Central Nervous System Metastases in Breast Cancer
For many years it has been debated whether patients with a 
limited number of brain metastases (BM) may benefit from a 
whole-brain RT (WBRT) after local treatment of these le-
sions. Recently published data suggest that such an additional 
procedure should be restricted to individual cases because 
overall survival was not prolonged [106]. Moreover, pre-
liminary results of a multicenter phase II trial indicate that an 
upfront therapy with lapatinib and capecitabine could be an 
option for patients with multiple BM caused by HER2-posi-
tive breast cancer [9].
Targeted Therapy in MBC
Despite many recently published and further ongoing studies 
examining targeted therapy in breast cancer, recommenda-
tions in the update 2012 with regard to MBC are confined to 
2 major clinical relevant topics: the combination treatment 
with pertuzumab plus trastuzumab plus docetaxel in HER2-
positive MBC and the combination everolimus plus exemes-
tane in HR-positive MBC; both have got the recommendation 
level AGO +. Another field of clinically relevant discussion 
focuses on the evaluation of bevacizumab combination treat-
ment with diverse cytotoxic agents. (For targeted therapy 
combined with cytotoxic agents in the adjuvant setting, see 
the respective section.)
Pertuzumab
Pertuzumab, an anti-HER2 humanized monoclonal antibody 
that inhibits receptor dimerization, has a mechanism of action 
that is complementary to that of trastuzumab. In the recently 
published phase III study, 808 patients with HER2-positive 
MBC received pertuzumab plus trastuzumab plus docetaxel 
or trastuzumab, docetaxel alone as first-line treatment. Addi-
tion of pertuzumab significantly improved the primary end 
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Early exercise therapy after surgery, however, does help to 
improve upper limb dysfunction, but increases daily wound 
drainage loss and prolongs the need for drainage therapy 
[123] (LoE 1a A, AGO +). Additionally, the Cochrane review 
on the value of thymic peptides in cancer treatment has finally 
been published: There was preliminary evidence that thymic 
peptides lowered the risk of severe infectious complications in 
patients undergoing chemotherapy or RT, but there was no 
convincing indication that thymic peptides could help to im-
prove cancer survival [208] (LoE 2a B, AGO +/–). Finally, 
new evidence accumulates that phytoestrogens are more 
likely friend than foe in the fight against BC. Flaxseed, an im-
portant source of enterolactone-bearing lignans, has once 
more been investigated in breast cancer survivors. Buck et al. 
[28] found in 1140 postmenopausal breast cancer patients that 
high serum enterolactone levels were associated with impro-
ved survival. These findings were supported by a recent meta-
analysis indicating a significant inverse association between 
serum enterolactone and postmenopausal breast cancer risk, 
which was stronger for ER– PR– than for ER+ PR+ tumors 
[211]. Interestingly, soy food consumption was significantly 
associated with decreased risk of death and recurrence in 
 Chinese breast cancer survivors [167]. The AGO grade of 
 recommendation for soy food for the whole group of patients 
with advanced breast cancer is LoE 2b B, AGO +/–, and 
for the patients with HR-positive breast cancer LoE 2b B, 
AGO –. In contrast to earlier reports, vitamin use shortly 
after breast cancer diagnosis was associated with reduced 
mortality and recurrence risk [137]. The AGO judgment for 
antioxidants after finishing RT is LoE 2b B, AGO +/–. How-
ever, the effects of antioxidant supplement use after diagnosis 
differ by the type of antioxidants administered.
While certain Chinese medicinal herbs seem to alleviate 
 aspects of treatment-related side effects [212], the Cochrane 
review by Milazzo et al. [127] warns that laetrile lacks any 
promise of efficacy but could bear significant risks due to 
 unforeseen toxicity (LoE 1c D, AGO –).
Breast cancer patients require comprehensive guidance 
with respect to possibilities, effectiveness, and side effects of 
complementary and alternative therapeutic approaches. 
Therefore, practicing physicians are required to inform them-
selves about the expectations of their patients. Not infre-
quently, these expectations with regard to the efficacy of 
 complementary and alternative medicine (CAM) are unreal-
istically exaggerated. Only cooperative guidance of patients 
by informed oncologists can prevent communication break-
down and avert the danger of conflicting therapies and drug 
interferences.
Options for Primary Prevention:  
Modifiable Lifestyle Factors
There have been no substantial changes in the AGO recom-
mendations compared to 2011.
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